Update shared on01 Aug 2025
Fair value Decreased 10%Consensus revenue growth forecasts for PetMed Express have deteriorated further into negative territory, driving a lower analyst price target from $3.35 to $3.00.
What's in the News
- PetMed Express received a notice from Nasdaq for not timely filing its annual report, with a deadline to submit a compliance plan and potentially regain compliance by late December.
- The company announced delays in filing its annual 10-K, citing ongoing work to complete its financial statements.
- SilverCape Investments Limited is engaging with management on strategic and performance issues and may seek board representation.
- PetMed Express formed a new partnership with Wagmo, providing exclusive product savings to Wagmo members.
Valuation Changes
Summary of Valuation Changes for PetMed Express
- The Consensus Analyst Price Target has significantly fallen from $3.35 to $3.00.
- The Consensus Revenue Growth forecasts for PetMed Express has significantly fallen from -3.0% per annum to -5.0% per annum.
- The Future P/E for PetMed Express has fallen from 8.45x to 7.87x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.